---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-096417"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2026-08-14T11:05:24+00:00"
generated_at: "2026-08-14T11:10:05.146526+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tvardi Q2 2026 net loss $6.5M; TTI-109 to target UC after positive healthy-volunteer data

## Summary
- Net loss $6.5M vs net income $4.2M in Q2 2025 (prior year had $12.7M non-cash gain); EPS -$0.69.
- TTI-109 healthy-volunteer topline confirms prodrug design, improved tolerability, and immune-cell reductions.
- Selected ulcerative colitis (UC) as first TTI-109 indication; >1.25M US patients, ~$3B US market.
- Cash $15.8M at June 30, 2026, down from $30.8M; funds operations through HCC readout into Q3 2027.
- Upcoming: KOL webinar Aug 19, 2026; TTI-101 HCC data 4Q 2026; UC trial start 2027 subject to IND/funding.

## SEC filing metadata
- accession: 0001104659-26-096417
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2026-08-14T11:05:24+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465926096417/0001104659-26-096417-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465926096417/tm2623143d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-096417
- JSON: https://secwatch.observer/filing/0001104659-26-096417.json
- Plain text: https://secwatch.observer/filing/0001104659-26-096417.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.